A new Phase III Clinical Trial for Patients who have been treated with imatinib, sunitinib, and regorafenib was posted to clinicaltrials.gov in November 2017.
Please see the following link for the latest information:
This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of Deciphera’s DCC-2618 to placebo in patients who have received treatment with prior anticancer therapies.
Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients will be randomized in a 2:1 ratio to DCC‑2618 150 mg QD or placebo